These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22734029)

  • 1. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Taylor KL; Luta G; Miller AB; Church TR; Kelly SP; Muenz LR; Davis KM; Dawson DL; Edmond S; Reding D; Mabie JE; Riley TL
    J Clin Oncol; 2012 Aug; 30(22):2768-75. PubMed ID: 22734029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
    Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Grubb RL; Pinsky P; Prorok PC; Andriole GL
    Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
    O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
    PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid use by cancer status and time since diagnosis among older adults enrolled in the Prostate, Lung, Colorectal, and Ovarian screening trial in the United States.
    Durham DD; Strassels SA; Pinsky PF
    Cancer Med; 2021 Mar; 10(6):2175-2187. PubMed ID: 33638315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors.
    Davis KM; Kelly SP; Luta G; Tomko C; Miller AB; Taylor KL
    Urology; 2014 Aug; 84(2):300-6. PubMed ID: 24975711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.
    Sharma A; Hostetter J; Morrison J; Wang K; Siegel E
    J Digit Imaging; 2016 Apr; 29(2):160-4. PubMed ID: 26385814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US.
    Kc M; Fan J; Hyslop T; Hassan S; Cecchini M; Wang SY; Silber A; Leapman MS; Leeds I; Wheeler SB; Spees LP; Gross CP; Lustberg M; Greenup RA; Justice AC; Oeffinger KC; Dinan MA
    JAMA Netw Open; 2023 Jul; 6(7):e2323115. PubMed ID: 37436746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Doria-Rose VP; Laiyemo AO; Church T; Yokochi LA; Yurgalevitch S; Rathmell J; Andriole GL; Buys S; Crawford ED; Fouad M; Isaacs C; Lamerato L; Reding D; Prorok PC; Berg CD;
    J Natl Cancer Inst; 2012 Feb; 104(4):280-9. PubMed ID: 22298838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast, colorectal and prostate cancer screening for cancer survivors and non-cancer patients in community practices.
    Hudson SV; Hahn KA; Ohman-Strickland P; Cunningham RS; Miller SM; Crabtree BF
    J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S487-90. PubMed ID: 19838855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
    Simpson NK; Johnson CC; Ogden SL; Gamito E; Trocky N; McGuire C; Martin J; Barrow S; Lamerato L; Flickinger LM; Broski KG; Engelhard D; Hilke C; Bonk J; Gahagan B; Gren LH; Childs J; Lappe K; Fouad M; Thompson J; Sullivan D;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):356S-378S. PubMed ID: 11189688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Andriole GL
    Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Miller AB; Yurgalevitch S; Weissfeld JL;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Stallings FL; Ford ME; Simpson NK; Fouad M; Jernigan JC; Trauth JM; Miller DS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):379S-389S. PubMed ID: 11189689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System.
    Lamerato LE; Marcus PM; Jacobsen G; Johnson CC
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):827-33. PubMed ID: 18398023
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.